Detalhe da pesquisa
1.
Fungal sensing by dectin-1 directs the non-pathogenic polarization of TH17 cells through balanced type I IFN responses in human DCs.
Nat Immunol
; 23(12): 1735-1748, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36456734
2.
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med
; 388(26): 2444-2455, 2023 Jun 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37379135
3.
Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.
N Engl J Med
; 388(21): 1966-1980, 2023 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37224198
4.
Clinical and humoral responses after SARS-CoV-2 breakthrough infections in patients with immunosuppressants.
J Allergy Clin Immunol
; 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38763170
5.
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Lancet
; 401(10383): 1159-1171, 2023 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36871574
6.
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
N Engl J Med
; 385(14): 1280-1291, 2021 09 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34587385
7.
Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.
Clin Gastroenterol Hepatol
; 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38723981
8.
mRNA-1273 vaccinated inflammatory bowel disease patients receiving TNF inhibitors develop broad and robust SARS-CoV-2-specific CD8+ T cell responses.
J Autoimmun
; 144: 103175, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38387105
9.
Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies.
Scand J Gastroenterol
; 59(2): 169-175, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37961895
10.
Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's Disease.
Dig Dis Sci
; 2024 Apr 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38568396
11.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet
; 399(10340): 2031-2046, 2022 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644155
12.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
Lancet
; 399(10340): 2015-2030, 2022 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644154
13.
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Lancet
; 399(10341): 2113-2128, 2022 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644166
14.
Intestinal Ultrasound Is Accurate to Determine Endoscopic Response and Remission in Patients With Moderate to Severe Ulcerative Colitis: A Longitudinal Prospective Cohort Study.
Gastroenterology
; 163(6): 1569-1581, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36030056
15.
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease.
Gastroenterology
; 162(2): 495-508, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34748774
16.
Reliability and Responsiveness of Histologic Indices for the Assessment of Crohn's Disease Activity.
Clin Gastroenterol Hepatol
; 2023 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38056798
17.
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
Gastroenterology
; 162(6): 1650-1664.e8, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35134323
18.
Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 21(5): 1338-1347, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36031093
19.
Standardizing Scoring Conventions for Crohn's Disease Endoscopy: An International RAND/UCLA Appropriateness Study.
Clin Gastroenterol Hepatol
; 21(11): 2938-2950.e6, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37308036
20.
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results.
Gastroenterology
; 162(7): 1876-1890, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35122766